ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
98 114,30
0,36%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Catabasis Pharmaceuticals Inc (CATB) Cours

Catabasis Pharmaceuticals Inc

Catabasis Pharmaceuticals Inc (CATB)

NASDAQ
8,54
0,00
(0,00%)
Fermé 21 Décembre 10:00PM
Retardé de 15 minutes
0,00
0,00
(0,00%)
Après les heures de négociation: -
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
8,54
Prix Achat
8,45
Prix Vente
8,63
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Cap du marché
309,968M
Clôture Veille
8,54
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
-
Actions en circulation
36 296 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-4,25
Bénéfice par action (BPA)
-2,01
Chiffre d'affairess
-
Bénéfice net
-72,89M

À propos de Catabasis Pharmaceuticals Inc

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.astriatx.com
Siège social
Wilmington, Delaware, USA
Fondé
-

CATB Dernières nouvelles

Plus de nouvelles

Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

-- Astria Reflects Company’s Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin...

08 Septembre 2021
Business Wire

Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “We are...

09 Août 2021
Business Wire

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the...

04 Août 2021
Business Wire

Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide...

07 Juillet 2021
Business Wire

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide...

14 Mai 2021
Business Wire

 Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

 -- QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein, Progresses in Preclinical Development for the Treatment of Hereditary Angioedema -- -- Strong Cash...

13 Mai 2021
Business Wire

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

-- Recently Completed Acquisition of Quellis Biosciences Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the...

11 Mars 2021
Business Wire

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences   

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide...

02 Mars 2021
Business Wire

Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema Company Plans to...

29 Janvier 2021
Business Wire

Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

-- Cash and Cash Equivalents Totaled $52.9 Million as of September 30, 2020 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for...

12 Novembre 2020
Business Wire
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CATB - Frequently Asked Questions (FAQ)

What is the current Catabasis Pharmaceuticals share price?
The current share price of Catabasis Pharmaceuticals is US$ 8,54
How many Catabasis Pharmaceuticals shares are in issue?
Catabasis Pharmaceuticals has 36 296 000 shares in issue
What is the market cap of Catabasis Pharmaceuticals?
The market capitalisation of Catabasis Pharmaceuticals is USD 309,97M
What is the 1 year trading range for Catabasis Pharmaceuticals share price?
Catabasis Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Catabasis Pharmaceuticals?
The price to earnings ratio of Catabasis Pharmaceuticals is -4,25
What is the reporting currency for Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals reports financial results in USD
What is the latest annual profit for Catabasis Pharmaceuticals?
The latest annual profit of Catabasis Pharmaceuticals is USD -72,89M
What is the registered address of Catabasis Pharmaceuticals?
The registered address for Catabasis Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Catabasis Pharmaceuticals website address?
The website address for Catabasis Pharmaceuticals is www.astriatx.com
Which industry sector does Catabasis Pharmaceuticals operate in?
Catabasis Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
121,03M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
78,06M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
34M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,94k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
121,95M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,5M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,63M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,84M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
8,58M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
5,96M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,33M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
310,19M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
306,25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
293,22M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
281,23M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CATB
Catabasis Pharmaceuticals
BIT
SGFM
Graniteshares 1x Short G...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés